Profile data is unavailable for this security.
About the company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.
- Revenue in USD (TTM)24.17bn
- Net income in USD5.66bn
- Incorporated1933
- Employees23.30k
- LocationBristol-Myers Squibb Co430 E 29th St Fl 14NEW YORK 10016-8367United StatesUSA
- Phone+1 (212) 546-4000
- Fax+1 (302) 655-5049
- Websitehttps://www.bms.com/
Mergers & acquisitions
| Acquired company | BMY:NYQ since announced | Transaction value |
|---|---|---|
| Celgene Corp | 14.34% | 79.38bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 22.37bn | 2.71bn | 84.87bn | 11.00k | 31.86 | 4.12 | 20.68 | 3.79 | 2.11 | 2.09 | 17.47 | 16.27 | 0.3623 | 5.37 | 6.60 | 2,033,182.00 | 4.36 | 23.08 | 5.20 | 28.22 | 79.60 | 84.37 | 12.04 | 43.52 | 2.87 | 6.07 | 0.5425 | 17.01 | -15.24 | 14.59 | -46.06 | 12.17 | 37.10 | -- |
| Eli Lilly And Co | 22.64bn | 4.44bn | 114.87bn | 38.68k | 25.76 | 33.98 | 20.22 | 5.07 | 4.64 | 8.21 | 23.54 | 3.52 | 0.5488 | 1.39 | 4.36 | 585,421.40 | 10.77 | 6.48 | 14.88 | 9.00 | 77.78 | 74.01 | 19.62 | 11.69 | 0.8829 | 22.10 | 0.8147 | 87.08 | 7.36 | 1.22 | 99.27 | -6.17 | 22.52 | 2.80 |
| AbbVie Inc | 32.87bn | 3.32bn | 128.63bn | 30.00k | 38.94 | -- | 24.28 | 3.91 | 2.23 | 2.18 | 22.17 | -5.56 | 0.5233 | 4.07 | 5.81 | 1,095,567.00 | 5.32 | 9.30 | 7.21 | 12.12 | 77.01 | 77.24 | 10.17 | 18.82 | 1.04 | 9.45 | 1.27 | 83.76 | 16.08 | 11.75 | 1.06 | 6.83 | 5.38 | 17.54 |
| Amgen, Inc. | 23.40bn | 8.07bn | 138.90bn | 21.50k | 17.94 | 12.75 | 13.81 | 5.94 | 13.03 | 13.03 | 37.75 | 18.33 | 0.3688 | 1.34 | 6.64 | 1,088,140.00 | 12.72 | 9.96 | 15.56 | 11.42 | 82.05 | 81.15 | 34.48 | 32.60 | 2.59 | 14.98 | 0.7316 | 40.32 | 3.93 | 4.92 | 3.90 | 10.56 | 1.27 | 22.94 |
| Bristol-Myers Squibb Co | 24.17bn | 5.66bn | 140.53bn | 23.30k | 17.33 | 5.53 | 21.85 | 5.81 | 3.46 | 3.46 | 14.77 | 10.83 | 0.5303 | 5.70 | 5.43 | 1,037,468.00 | 12.47 | 10.05 | 16.07 | 13.92 | 70.85 | 73.87 | 23.52 | 17.90 | 3.72 | 19.21 | 0.5843 | 74.94 | 8.59 | 6.61 | 27.49 | 14.19 | 12.11 | 2.71 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2019 | 132.11m | 8.11% |
| Wellington Management Co. LLPas of 30 Sep 2019 | 109.66m | 6.73% |
| BlackRock Fund Advisorsas of 30 Sep 2019 | 77.27m | 4.74% |
| SSgA Funds Management, Inc.as of 30 Sep 2019 | 68.61m | 4.21% |
| Dodge & Coxas of 30 Sep 2019 | 50.45m | 3.10% |
| Fidelity Management & Research Co.as of 30 Sep 2019 | 40.42m | 2.48% |
| Renaissance Technologies LLCas of 30 Sep 2019 | 32.76m | 2.00% |
| Columbia Management Investment Advisers LLCas of 30 Sep 2019 | 29.24m | 1.80% |
| Geode Capital Management LLCas of 30 Sep 2019 | 27.42m | 1.68% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2019 | 24.45m | 1.50% |
